hycanthone has been researched along with Pancreatic Neoplasms in 3 studies
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.
hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy." | 2.67 | Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. ( Earle, JD; Foley, JF; Krook, JE; Kvols, LK; McKenna, PJ; Schutt, AJ; Tschetter, LK; Twito, DI; Wieand, HS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horwitz, JP | 1 |
| Massova, I | 1 |
| Wiese, TE | 1 |
| Besler, BH | 1 |
| Corbett, TH | 2 |
| Perni, RB | 1 |
| Wentland, MP | 1 |
| Huang, JI | 1 |
| Powles, RG | 1 |
| Aldous, S | 1 |
| Klingbeil, KM | 1 |
| Peverly, AD | 1 |
| Robinson, RG | 1 |
| Jones, JL | 1 |
| Mattes, KC | 1 |
| Rake, JB | 1 |
| Coughlin, SA | 1 |
| Earle, JD | 1 |
| Foley, JF | 1 |
| Wieand, HS | 1 |
| Kvols, LK | 1 |
| McKenna, PJ | 1 |
| Krook, JE | 1 |
| Tschetter, LK | 1 |
| Schutt, AJ | 1 |
| Twito, DI | 1 |
1 trial available for hycanthone and Pancreatic Neoplasms
| Article | Year |
|---|---|
Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Evaluation Studies as Top | 1994 |
2 other studies available for hycanthone and Pancreatic Neoplasms
| Article | Year |
|---|---|
Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Mice; Models, Molecular; Pancreatic Ducts | 1994 |
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enz | 1998 |